Back

longer dual antiplatelet therapy beyond 9 months does not influence neointimal condition after second generation drug eluting stent implantation

27 August 2016 (12:49 - 12:56)
Organised by:
Congress Presentation Part of: Dual antiplatelet therapy: the long and the short of it! Thrombosis and platelets ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Yutaka Goryo

Nara Prefectural Seiwa Medical Center, Nara (Japan)

5 More presentations in this session

Presentation thumbnail
Clinical outcomes in patients with diabetes mellitus receiving dual antiplatelet therapy more than 12 months after second-generation drug eluting stent implantation
Doctor S. Cho (Goyang, KR)
Abstract Slides
Presentation thumbnail
Longer-term oral antiplatelet use in stable post-MI patients: Insights from the TIGRIS study
Doctor S. Goodman (Toronto, CA)
Abstract
Presentation thumbnail
Duration of dual antiplatelet therapy in patients treated with second generation drug-eluting stents: a systematic review and meta-analysis
Doctor M. Bianco (Orbassano, IT)
Abstract Slides
Presentation thumbnail
Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation in patients with or without diabetes: a patient-level meta-analysis of randomised trials
Doctor G. Gargiulo (Napoly, IT)
Abstract Slides
Presentation thumbnail
Long term dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomised studies
Doctor G. Ferrante (Milan, IT)
Abstract Slides

Access the full session

Session thumbnail
Dual antiplatelet therapy: the long and the short of it!

The Event

Event poster

ESC Congress 2016

27 August 2016 12:49 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources